Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF), a pioneer in synthetic anti-infectives, has been granted a new Patent Family 4 by the Canadian Patent Office.
This patent, entitled 'Process for Preparation of Biologically Active Copolymer', extends until 2041 and marks a significant advancement in the field of anti-infectives.
Key aspects of the granted Canadian Patent pertain to RECCE® 327 (R327) and RECCE® 529 (R529), and include:
- the process for preparing RECCE® anti-infectives.
- the application of R327 and R529 for disease treatment, especially in bacterial and viral infections. The scope of application extends to various conditions like burn wounds, urinary tract infections, gonorrhoea, influenza and SARS-CoV2.
The patent also covers diverse methods of administering these anti-infectives, including orally, through inhalation, transdermally or by injection (intravenous, intramuscular or into the bloodstream).
Additional forms of application include aerosol, gel, topical foam or ointment, and the option to impregnate them into dressings for skin or mucous membrane application.
“Significant potential”
Recce CEO James Graham said: “We thank the Canadian Government for their recognition of the significant potential of Recce’s new class of anti-infectives.
“This achievement further extends our global patent portfolio and comes as a welcome new set of marketing/manufacturing monopolies in Canada, to at least January 2041.”
Canadian support
This is the first of Recce’s wholly owned patents granted in Canada, with further patent cooperation treaty country (PCT) submissions in respective stages of review.
In July 2023, the company received A$98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
The program is administered by the Canada Revenue Agency and is aimed at incentivising businesses to conduct R&D in Canada, encouraging innovation and technological advancements.
About Recce
Recce Pharmaceuticals is developing a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
- RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms;
- RECCE® 435 as an orally administered therapy for bacterial infections; and
- RECCE® 529 for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.